Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 [BG 12] in Subjects With Relapsing-Remitting Multiple Sclerosis

Trial Profile

Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 [BG 12] in Subjects With Relapsing-Remitting Multiple Sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Dimethyl fumarate (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Biogen Idec
  • Most Recent Events

    • 28 Apr 2017 Results of an integrated analysis (n=2470) of phase III (DEFINE, CONFIRM and ENDORSE-extension) and phase IIb Dimethyl Fumarate (DMF) studies reporting long-term absolute lymphocyte count (ALC) and post-DMF ALC data, presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 25 Oct 2008 Results have been published in the Lancet.
    • 18 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top